RFA-HD-23-004: Bioprinted Tissue Constructs for Obstetric, Gynecologic, and Pediatric Applications (R01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 27, 2022.
From the official notice on Grants.gov, last changed May 27, 2022. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNICHD
- Median yearly award$604,982
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-HD-23-004 were run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HD-23-004 in the NIH Guide.
Key dates
| Posted | May 27, 2022 |
|---|---|
| Deadline | July 27, 2022 |
| Archived by Grants.gov | September 1, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $604,982; it allows up to $500,000 per award.
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will utilize 3D bioprinting technologies to develop tissue constructs for long-term use that will adapt to the needs of growing children, and for obstetric and gynecological conditions. The overall goal of this initiative is to promote the clinical translation of bioprinted tissue constructs by helping to identify and working to overcome current barriers to preclinical product development, validation and verification. This will ultimately enable evidence generation for regulatory approval and human testing of mature bioprinted tissue constructs addressing the unmet needs of NICHD mission-relevant gynecologic, obstetric and pediatric diseases and disorders. Of note, this FOA is not intended for early stage, hypothesis validation of new bioprinted tissue constructs not yet mature for pursuing clinical translation or to support large scale clinical trials using bioprinted tissue constructs.
Funded under RFA-HD-23-004 so far
NIH funded 3 projects under RFA-HD-23-004 in fiscal 2023 to 2026, at 3 institutions. The median yearly award was $604,982.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| 3D Bioprinted Nipple-Areolar Complex Implants | Univ of Maryland, College Park | 2026 | $490,649 |
| Production of 3D Bioprinted Autologous Vaginal Tissue Constructs for Reconstructive Applications | Wake Forest University Health Sciences | 2026 | $599,666 |
| Pre-clinical validation of 3D-printed nerve conduits for pediatric peripheral nerve repair | University of California, San Diego | 2026 | $632,740 |
Who has won Child Health and Human Development Extramural Research grants before
From fiscal 2021 to 2025, Child Health and Human Development Extramural Research (93.865) awarded $6.0 billion across 6,026 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 167 | $178 million |
| The Johns Hopkins University | Maryland | 133 | $146 million |
| University of Washington | Washington | 114 | $131 million |
| Baylor College of Medicine | Texas | 116 | $124 million |
| The Leland Stanford Junior University | California | 104 | $116 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HD-23-004 still open?
No. It closed on July 27, 2022.
Who can apply for Bioprinted Tissue Constructs for Obstetric, Gynecologic, and Pediatric Applications (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Bioprinted Tissue Constructs for Obstetric, Gynecologic, and Pediatric Applications (R01 Clinical Trial Optional)?
Closed July 27, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-HD-23-004?
NIH RePORTER lists 3 projects funded under RFA-HD-23-004 in fiscal 2023 to 2026, at 3 institutions. The most were at Univ of Maryland, College Park, Wake Forest University Health Sciences, University of California, San Diego.
Who has won Child Health and Human Development Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Johns Hopkins University, University of Washington. The program made 6,026 awards worth $6.0 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)